Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Onco
Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
More...
|